1
NU 518 MODULE 7 EXAM 2026/2027 |
ADVANCED PHARMACOLOGY | 40 VERIFIED
Q&A | DETAILED RATIONALES | NGN-
ALIGNED | PASS GUARANTEED – A+ GRADED
SECTION 1: GASTROINTESTINAL PHARMACOLOGY - Questions 1-10
Q1: Infliximab Use in Crohn's Disease
The student is reviewing inflammatory bowel disease medications. A patient with moderate-to-
severe Crohn's disease is prescribed infliximab. What is the mechanism of action of this medication?
A. Monoclonal antibody against TNF-alpha
B. Integrin receptor antagonist
C. Interleukin-12/23 inhibitor
D. Janus kinase inhibitor
Correct Answer: A
Rationale: Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha
(TNF-α) and neutralizes its pro-inflammatory effects. It is used for moderate-to-severe Crohn's
disease and ulcerative colitis. Vedolizumab is an integrin antagonist. Ustekinumab inhibits IL-12/23.
Tofacitinib is a JAK inhibitor. [100% CORRECT]
Q2: Vedolizumab Mechanism
The student is reviewing IBD medications. What is the mechanism of action of vedolizumab?
A. Alpha-4-beta-7 integrin antagonist, blocking lymphocyte trafficking to the gut
B. TNF-alpha inhibitor
C. IL-12/23 inhibitor
D. JAK inhibitor
Correct Answer: A
Rationale: Vedolizumab is a humanized monoclonal antibody that binds to the alpha-4-beta-7
integrin on lymphocytes, preventing their migration into the gastrointestinal tract. It is used for
ulcerative colitis and Crohn's disease with a gut-selective mechanism. [100% CORRECT]
Q3: Ustekinumab Mechanism in IBD
The student is reviewing IBD medications. What is the mechanism of action of ustekinumab in
Crohn's disease?
, 2
A. Inhibits IL-12 and IL-23, reducing T-cell differentiation
B. TNF-alpha inhibitor
C. Integrin antagonist
D. JAK inhibitor
Correct Answer: A
Rationale: Ustekinumab is a monoclonal antibody that targets the p40 subunit of IL-12 and IL-23,
inhibiting T-cell differentiation and cytokine production. It is used for moderate-to-severe Crohn's
disease and ulcerative colitis. [100% CORRECT]
Q4: Tofacitinib Adverse Effect
The student is reviewing JAK inhibitors. Which serious adverse effect is associated with tofacitinib?
A. Infections and thrombosis
B. Hypertension
C. Bradycardia
D. Hyperglycemia
Correct Answer: A
Rationale: Tofacitinib is a JAK inhibitor used for ulcerative colitis and rheumatoid arthritis. It carries a
boxed warning for serious infections, malignancy, thrombosis, and major adverse cardiovascular
events. [100% CORRECT]
Q5: Sulfasalazine Adverse Effect
The student is reviewing IBD medications. Which adverse effect is associated with sulfasalazine?
A. Reversible oligospermia
B. Hypertension
C. Bradycardia
D. Hyperglycemia
Correct Answer: A
Rationale: Sulfasalazine can cause reversible oligospermia in men, as well as nausea, rash, and
hemolytic anemia in patients with G6PD deficiency. It is used for ulcerative colitis and rheumatoid
arthritis. [100% CORRECT]
Q6: Mesalamine Mechanism
The student is reviewing IBD medications. What is the mechanism of action of mesalamine?
A. Topical anti-inflammatory effect in the colon
B. TNF-alpha inhibitor
C. Integrin antagonist
D. JAK inhibitor
NU 518 MODULE 7 EXAM 2026/2027 |
ADVANCED PHARMACOLOGY | 40 VERIFIED
Q&A | DETAILED RATIONALES | NGN-
ALIGNED | PASS GUARANTEED – A+ GRADED
SECTION 1: GASTROINTESTINAL PHARMACOLOGY - Questions 1-10
Q1: Infliximab Use in Crohn's Disease
The student is reviewing inflammatory bowel disease medications. A patient with moderate-to-
severe Crohn's disease is prescribed infliximab. What is the mechanism of action of this medication?
A. Monoclonal antibody against TNF-alpha
B. Integrin receptor antagonist
C. Interleukin-12/23 inhibitor
D. Janus kinase inhibitor
Correct Answer: A
Rationale: Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha
(TNF-α) and neutralizes its pro-inflammatory effects. It is used for moderate-to-severe Crohn's
disease and ulcerative colitis. Vedolizumab is an integrin antagonist. Ustekinumab inhibits IL-12/23.
Tofacitinib is a JAK inhibitor. [100% CORRECT]
Q2: Vedolizumab Mechanism
The student is reviewing IBD medications. What is the mechanism of action of vedolizumab?
A. Alpha-4-beta-7 integrin antagonist, blocking lymphocyte trafficking to the gut
B. TNF-alpha inhibitor
C. IL-12/23 inhibitor
D. JAK inhibitor
Correct Answer: A
Rationale: Vedolizumab is a humanized monoclonal antibody that binds to the alpha-4-beta-7
integrin on lymphocytes, preventing their migration into the gastrointestinal tract. It is used for
ulcerative colitis and Crohn's disease with a gut-selective mechanism. [100% CORRECT]
Q3: Ustekinumab Mechanism in IBD
The student is reviewing IBD medications. What is the mechanism of action of ustekinumab in
Crohn's disease?
, 2
A. Inhibits IL-12 and IL-23, reducing T-cell differentiation
B. TNF-alpha inhibitor
C. Integrin antagonist
D. JAK inhibitor
Correct Answer: A
Rationale: Ustekinumab is a monoclonal antibody that targets the p40 subunit of IL-12 and IL-23,
inhibiting T-cell differentiation and cytokine production. It is used for moderate-to-severe Crohn's
disease and ulcerative colitis. [100% CORRECT]
Q4: Tofacitinib Adverse Effect
The student is reviewing JAK inhibitors. Which serious adverse effect is associated with tofacitinib?
A. Infections and thrombosis
B. Hypertension
C. Bradycardia
D. Hyperglycemia
Correct Answer: A
Rationale: Tofacitinib is a JAK inhibitor used for ulcerative colitis and rheumatoid arthritis. It carries a
boxed warning for serious infections, malignancy, thrombosis, and major adverse cardiovascular
events. [100% CORRECT]
Q5: Sulfasalazine Adverse Effect
The student is reviewing IBD medications. Which adverse effect is associated with sulfasalazine?
A. Reversible oligospermia
B. Hypertension
C. Bradycardia
D. Hyperglycemia
Correct Answer: A
Rationale: Sulfasalazine can cause reversible oligospermia in men, as well as nausea, rash, and
hemolytic anemia in patients with G6PD deficiency. It is used for ulcerative colitis and rheumatoid
arthritis. [100% CORRECT]
Q6: Mesalamine Mechanism
The student is reviewing IBD medications. What is the mechanism of action of mesalamine?
A. Topical anti-inflammatory effect in the colon
B. TNF-alpha inhibitor
C. Integrin antagonist
D. JAK inhibitor
